Terry Murphy’s Post

Announcing the Launch of a QuickFire Challenge to Leverage Technologies to Increase Representation in Immune-Mediated Disease Clinical Trials. Data on treatment effectiveness for Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA) and other Immune-Mediated Diseases (IMDs) are insufficient, particularly among ethnic groups who are disproportionately underrepresented in clinical research. With nearly 30 million people living with IMDs worldwide, finding equitable solutions is crucial. Innovators who have unique solutions to increase diverse representation in global clinical trials for IMDs are invited to apply to the Leveraging Technology to Drive Representative Clinical Trials #QuickFireChallenge for the chance to receive grant funding from a total pool of $250K, access to the global Johnson & Johnson Innovative Medicine – JLABS network, and mentorship from experts across Johnson & Johnson by 13th September 2023 at https: https://jji.jnj/IMMDEI24 #MyCompany

Data on treatment effectiveness for inflammatory bowel disease (IBD), rheumatoid arthritis and other immune-mediated diseases (IMDs) are insufficient, particularly among ethnic groups who are disproportionately underrepresented in clinical research. With nearly 30 million people living with IMDs worldwide, finding equitable solutions is crucial. Innovators who have unique solutions to increase diverse representation in global clinical trials for IMDs are invited to apply to the Leveraging Technology to Drive Representative Clinical Trials #QuickFireChallenge for the chance to receive grant funding from a total pool of $250K, access to the global Johnson & Johnson Innovation – JLABS network, and mentorship from experts across Johnson & Johnson by 09.13.24: https://jji.jnj/IMMDEI24.

In the dynamic landscape of life sciences, patient centricity has emerged as a key component, transforming the entire ecosystem. Patients are increasingly recognized as active participants in their healthcare journey, influencing key industry stakeholders. Sponsors and Clinical Research Organizations are leveraging advanced technologies to enhance patient engagement, ensuring smoother trial processes and improved data collection. Regulators are emphasizing the importance of patient-reported outcomes, shaping guidelines that prioritize patient perspectives. Investigators are adopting patient-centric trial designs, focusing on real-world evidence and biopharma companies are aligning their strategies with patient needs, from drug development to post-market surveillance. At RWS, we play a pivotal role in providing clear and patient-friendly communication throughout the life sciences continuum. We empower stakeholders to convey critical information through precise translation services, fostering genuine patient engagement and advancing patient-centric initiatives. For more info, reach out today! https://hubs.ly/Q02fhn610

Scaling is crucial in every industry, but the stakes are higher in clinical trials. By scaling effectively, we can ensure that more patients have access to innovative treatments and therapies, leading to improved health outcomes and quality of life. But where do you start? How can organizations navigate the complexities of scaling in clinical trials? Join me on March 20th, 11a EST/ 3p GMT as Nicole DuPont Latimer, CEO of Medrio, sits down with Khone Saysana and Walter S. of Roche to explore these questions and more. They will cover: 📈 The importance of adhering to standardized practices and protocols to enhance reliability, consistency, and successful outcomes. 🔬Strategies for achieving efficiencies through strategic scaling in drug development. 💼Insights into the future of clinical trials and how scaling will shape the landscape. Don't miss the opportunity to gain insights from industry leaders and experts. Click the link in my comments to register now and secure your spot! #ClinicalTrials #Scaling #Innovation

How do you know if a particular medicine is working? Traditionally, it takes guesswork on the physician’s part and time to find a drug that works for any given patient. But what if we could leverage digital biomarkers to measure the efficacy of a medication very quickly and course correct as needed? Rich Carter serves as Chief Digital Officer at Eli Lilly and Company, where he oversees the teams focused on innovation, user-centered design and digital health. On this episode of The Beat, Rich discuss the future of drug development and clinical trials, exploring what digital transformation means in the context of life sciences, explaining how technology can improve drug discovery and accelerate the timeline from discovery to market. 🎧 Listen now: https://lnkd.in/e7NpEQUx #TheBeat #HealthcareInnovation #DigitalHealth

Great to see progress across the #lifesciences #pharmaindustry on how #digitalinnovation can apply to #clinicaltrials at scale - "#digitalhealth solutions in #clinicalresearch and development can enable a shift from the traditional physical site-based model, with gaps in data collection between visits, to a modern innovative design, with 74–85% of trial assessments potentially being collected remotely, reducing the burden on patients and trial sites, while at the same time leading to more continuous data collection, new end points and more innovative trial designs." We are redefining what it means to be #patientcentric with innovations like this https://lnkd.in/eXJKGe2m

This quarter has seen several new reports and movement in the industry on diversifying and widening access to trials - all indicate that R.grid's automation engine is moving the needle in the right direction to make trials faster and more successful for everyone. Below are 4 key indicators across the industry: 1️⃣   Big pharma & local pharmacies >> Our tech is supporting community engagement in the new partnership between Boehringer Ingelheim, Walgreens and our partners at EmVenio Research. This shows how valuable it can be to extend beyond traditional methods and source participation from the community.(https://lnkd.in/ePxucWbZ) 2️⃣ Government medical research agency >> The National Institutes of Health has further highlighted the importance of finding and meeting people where they are and issued a $30 million, two-year pilot program to set up clinical research at primary care facilities in communities with underserved patient populations.(https://lnkd.in/eQE6uY2P) 3️⃣ Regulator >> The FDA published new draft guidance on their Diversity Action Plans Required for Certain Clinical Studies, designed to increase clinical study enrolment of historically underrepresented populations to improve the data, safety, and efficacy of research across all populations.(https://lnkd.in/e3YFw44V) 4️⃣ Consultancy >> A report published today by Trinity Life Sciences indicates that clinical trial sponsors are impeded by mistrust in the healthcare system in diverse communities. Again, this highlights the importance of community engagement to build trust. (https://lnkd.in/e6h5gJxC) Explore ways that we can support your trial planning, partners, or data to expand your reach at https://rgrid.tech/

From drug discovery and diagnostics to precision medicine and healthcare, Scotland's life sciences clusters are leading the way in developing tech-driven healthcare solutions to the world 💊🌍 Don't believe us? Check out the facts 👇 #ScotlandIsNow #DigitalHealth

From drug discovery and diagnostics to precision medicine and healthcare, Scotland's life sciences clusters are leading the way in developing tech-driven healthcare solutions to the world 💊🌍 Don't believe us? Check out the facts 👇 #ScotlandIsNow #DigitalHealth

Exciting move by AstraZeneca and awesome with Cristina Ortega Duran in front. Undoubtedly, patient experience is central when participating in clinical trials - most of us have seen “patchwork setups” leading to huge number of missing data, queries and dropouts and contrary seen excellent examples of patient centered data capture incl. devices, where the experience of patients and site staff have been in the center. Looking forward to see how Unify and Merlin will be leveraged and learning what underpinning data Merlin will be run upon…. After all, actionable predictions are most valuable when based on rich datasets 😉 #StayCuriousStayHungry